https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 miR-122 promotes virus-induced lung disease by targeting SOCS1 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45152 Wed 26 Oct 2022 13:51:48 AEDT ]]> Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43133 Tue 13 Sep 2022 15:14:32 AEST ]]> Beclomethasone has lesser suppressive effects on inflammation and antibacterial immunity than fluticasone or budesonide in experimental infection models https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38861 Streptococcus pneumoniae, mechanistically through inhibition of the antimicrobial peptide (AMP) cathelicidin. Using experiments in human cells and mouse infection models, we performed a head-to-head comparison of the effects of the major ICS agents used in COPD on innate immunity.]]> Mon 29 Jan 2024 17:53:07 AEDT ]]> Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42308 Camp-/-) and exogenous cathelicidin prevented ICS-mediated expansion of streptococci within the microbiota and improved bacterial clearance. Suppression of pulmonary immunity by ICS was mediated by augmentation of the protease cathepsin D. Collectively, these data suggest a central role for cathepsin D/cathelicidin in the suppression of antibacterial host defense by ICS in COPD. Therapeutic restoration of cathelicidin to boost antibacterial immunity and beneficially modulate the lung microbiota might be an effective strategy in COPD.]]> Mon 22 Aug 2022 10:35:15 AEST ]]> Rhinovirus-induced CCL17 and CCL22 in asthma exacerbations and differential regulation by STAT6 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41052 Mon 08 Aug 2022 14:57:26 AEST ]]>